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The activity of breast milk BSDL was assayed with or without phospholipids as extra-intestinal effec-
tor candidates. Phosphatidic acid, lysophosphatidic acid and platelet activating factor but not phos-
phatidylcholine and lysophosphatidylcholine stimulated BSDL activity at least as efﬁciently as
taurocholate. The apparent dissociation constants of PA and LPA at saturating concentrations of
three different substrates were between 0.1 and 13.4 lM and that of PAF was below or equal to
200 pM. Kinetic data suggested the existence of at least one binding site for each of these effectors.
PA, LPA and PAF are likely extra-intestinal modulators of BSDL activity.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Bile salt dependent lipase (EC 3.1.1.13) is an esterase active on
various lipids, including esters of glycerol, cholesterol and lipid sol-
uble vitamins, but unlike other lipases its activity on water insolu-
ble substrates is stimulated by primary bile salts [1–3]. In humans,
BSDL is secreted by pancreas and mammary glands, typically rep-
resenting about 4% of adult pancreatic juice proteins and less than
1% of breast milk proteins [4–6]. BSDL seems to play a major role in
the intestinal fat digestion at early life stages, before the lipolytic
system is mature [7–9]. Besides this digestive function, growing
data points out that this enzyme could have an important extra-
intestinal function: BSDL was found to be able to traverse the
intestinal mucosa towards blood circulation and was even re-
trieved in urines of healthy subjects [10–12]; it is secreted by
endothelial cells and monocytes–macrophages [13,14] and several
studies supported its involvement in the metabolism of lipopro-
teins, with impact on the cholesterol pools [15–17]. In link with
this, it was reported that BSDL is or could be involved in patho-
physiological processes, including atherosclerosis and inﬂamma-
tion [18–23].However, the enzymatic activity of BSDL in the extra-intestinal
compartments has never been clearly linked to whatever extra-
intestinal function. The concentration of bile acids in plasma was
reported to be 10 lM, or higher at postprandial conditions [15],
which is at least two orders of magnitude lower than the corre-
sponding intestinal concentration of bile acids, typically above
4 mM [24]. One therefore may suppose that bile acids are not ma-
jor extra-intestinal BSDL activators and suspects the existence of
other BSDL effector(s). So far, the activity of neutral cholesterol
esterase from human aorta macrophages on cholesteryl-oleate in
liposomes was found to be stimulated by phosphatidylserine,
phosphatidylinositol, cardiolipin and phosphatidic acid but not
by phosphatidylcholine, lysophosphatidylcholine, phosphatidyl-
ethanolamine or sphingomyeline [25]. Also, the activity of BSDL
from human pancreas on paranitrophenyl-butyrate was stimulated
by phosphatidylserine, phosphatidylinositol or phosphatidic acid,
but not by phosphatidylcholine [26].
Consequently, we screened putative extra-intestinal activators
of BSDL using pure BSDL from breast milk [6] and as substrates:
paranitrophenyl-butyrate (PNPC4), paranitrophenyl-laurate
(PNPC12), and cholesteryl-oleate (ChoC18). Taurocholate (TC)
served as a reference BSDL activator while testing phosphatidyl-
choline (PC), lysophosphatidylcholine (LPC), phosphatidyletha-
nolamine (PE) phosphatidic acid (PA), lysophosphatidic acid
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were discussed with respect to the extra-intestinal function of
BSDL.2. Materials and methods
2.1. Materials
PAF (1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine), LPA
(oleyl-L-a-lysophosphatidic acid), LPC (oleyl-sn-glycero-3-phos-
phocholine), PNPC4, ChoC18, horseradish peroxidase and choles-
terol oxidase were purchased from Sigma–Aldrich. TC and
PNPC12 were provided by Fluka-Biochemika and paranitrophenol
by Biomedicals (Illkirch, France). PC (1,2-dioleoyl-sn-glycero-3-
phosphatidylcholine), PE (1,2-dioleoyl-sn-glycero-3-phosphatidyl-
ethanolamine) and PA (1,2-dioleoyl-sn-glycero-3-phosphatidic
acid) were purchased from Larodan Fine Chemicals (Malmö, Swe-
den). The enzyme was freshly puriﬁed to homogeneity from breast
milk as described elsewhere [6].
2.2. Solubilization of substrates and ligands
TC was solubilized by gentle vortexing in the enzyme assay buf-
fer Tris/HCl (0.1 M, pH 7.4, 0.15 M NaCl). Stock solutions of phos-
pholipids, lysophospholipids and PAF were prepared in
chloroform/methanol (1:1), then bubbled with nitrogen and stored
at 20 C. For use, appropriate amounts of these lipids were dried
in 1.5 ml Eppendorf tubes using Speed Vacuum system, and then
dissolved in the enzyme assay buffer by mean of vigorous vor-
texing and subsequent sonication (for 5 min). Appropriate dilu-
tions were made for screening the effects of tested lipids. The
substrates PNPC4, PNPC12 and ChoC18 were dissolved in ethanol
and diluted accordingly. Ethanol has no effect on BSDL activity un-
der these experimental conditions [27].
2.3. Enzyme assay
In the case of paranitrophenyl esters, liberation of PNP was con-
tinuously monitored at 405 nm using microplate reader. Reaction
took place in 200 ll at 37 C for 3 min in the presence or absence
of each BSDL candidate effector. The reaction started by addition
of BSDL (20 ll) using multichannel pipette. Under these conditions,
the molar extinction coefﬁcient of PNP was 8300 M1 cm1, which
is slightly lower than that (11500 M1 cm1) previously reported
[28]. Activity on cholesteryl-oleate was measured according to
coupled cholesterol oxidase and peroxidase activities [29]. The ﬁ-
nal product (mono-imino-p-benzoquinone) was monitored contin-
uously during 5 min at 500 nm. Free cholesterol was used instead
of cholesteryl-oleate for the calibration curves.
2.4. Kinetic approach
The initial velocity expressed as lMmin1 corresponded to the
slopes of the stationary phases of the kinetic plots, with correlation
coefﬁcients above 0.98. The spontaneous hydrolysis of PNPC4 and
that PNPC12 were subtracted from those monitored in the presence
of BSDL. The catalytic constant (kcat, (s1)) was determined using
100 kDa as molecular mass for BSDL [6].
In a ﬁrst set of experiments, the effects of putative BSDL effec-
tors were screened within large interval of concentration and using
saturating concentrations of PNPC4, PNPC12 and cholesteryl-oleate.
For each putative effector, the concentrations the effects of which
ﬁt the Michaelis–Menten kinetic model were used for calculation
of kcat and of apparent dissociation constant (Kd), using GraphPad
prism program. In a second set of experiments, the kineticparameters of BSDL (kcat and Km) with PNPC12 as substrate were
determined in the absence or presence of sub-micellar concentra-
tions the already identiﬁed BSDL activators.
Each of putative BSDL activators was incubated alone in the
reaction medium with each of the three substrates but no notice-
able product release was observed, except the spontaneous decay
of PNPC4 and PNPC12. The kinetic experiments were repeated at
least four times and each replicate was used for determination of
the apparent kinetic constants of BSDL.
2.5. Statistical analysis
Statistical analyses of data were performed using the ANOVA
test of XLSTAT 2010 (Addinsoft, Paris, France). The model
Y ¼ aþ bItreatmentþ i, was used to analyse the treatment effect
(with effector candidate) for each substrate independently. The
statistical model Y ¼ aþ bItreatmentþ vjsubstrateþ dijtreatment
substrateþ kij was used to analyse the interaction treat-
ment⁄substrate for the variables Km, Kd and kcat, where a is the
mean effect, b, v and d are the adjusted coefﬁcients of the ﬁxed ef-
fects in the model and e is the random error associated with kth
observation of the ith treatment and the jth substrate. Contrasts
were computed using least signiﬁcant difference Fisher’s test to
compare the difference between each treatment and the difference
between each interaction. The treatment effects for each substrate
and the interaction ‘‘treatment⁄substrate’’ were considered statis-
tically signiﬁcant at P < 0.05.3. Results and discussions
3.1. Screening BSDL putative effectors
As expected, BSDL performed basal activity on the two artiﬁcial
substrates PNPC4 and PNPC12 (Fig. 1) and the stimulating effect of
TC on the hydrolysis of these two substrates is similar to that pre-
viously reported [6,28]. In addition, PA, LPA and PAF exhibited
stimulating effects on the same substrates at least as efﬁciently
as TC. Conversely, PE, PC and LPC exhibited only slight effects, if
any, on BSDL activity on PNPC4 and PNPC12. These data agree with
those previously obtained for PA and PC with PNPC4 as substrate
[26].
The kinetic plots of BSDL activators ﬁtted a rectangular hyper-
bola with high correlation coefﬁcient (R2 > 0.95), with the excep-
tion of PA with PNPC4 as substrate (R2 = 0.87) and of LPA with
PNPC12 as substrate (R2 = 0.91). The kinetic constants thus obtained
are summarized in Table 1. The catalytic constant of BSDL on
PNPC4 varied from 416 to 3680 s1 following the stimulating rank
LPA > PA > TC > PAF = PE, and from 173 to 396 s1 with PNPC12 as
substrate following the stimulating rank PA = LPA > PAF > TC = PE.
The apparent dissociation constants (Kd) of PA and LPA were quite
similar whether the substrate was PNPC4 or PNPC12 (4.7–13.4 lM);
those of TC and PE were different to each other depending on the
substrate in the interval 12–200 lM. More interestingly, Kd of
PAF was found to be much lower than those of PA, LPA, TC and
PE: 200 pM and 80 pM with PNPC4 and PNPC12 as substrates,
respectively.
No BSDL basal activity was observed with cholesteryl-oleate as
substrate (Fig. 2), in conformity with the kinetic behaviour of BSDL
on cholesterol esters [1,28]. Here again, the kinetic plots obey
Michaelis–Menten–Henri model at the lower concentrations of
effectors (see inserts). This means that at these concentrations,
BSDL performs homogeneous rather than interfacial catalysis,
although some sigmoidal tendency at low TC concentrations was
observed. For all the BSDL activators, the saturation plateau run-
ning at maximal velocity was followed by a deceleration phase
Fig. 1. The activity of BSDL on paranitrophenyl-butyrate (A) and on paranitro-
phenyl-laurate (B) and on both substrates (C) is stimulated by taurocholate,
(lyso)phosphatidic acid and platelet activating factor. Saturating concentrations of
PNPC4 (1.0 mM) and PNPC12 (0.2 mM) were used, with BSDL concentration of 1 and
2 nM, respectively. The inserts show the Michaelis–Menten plots at the lower
concentrations of the activators after subtracting basal activity.
Table 1
Catalytic constants (kcat) of BSDL with PNPC4, PNPC12, ChoC18 as substrates and
apparent dissociation constants (Kd)* of BSDL activators.
kcat (s1) Kd (lM)
PNPC4 PNPC12 ChoC18 PNPC4 PNPC12 ChoC18
PA 3069b 396a 2.6b 4.7b 13.4c 0.14c
LPA 3681a 391a 3.5a 5.3b 7.2c 4.8b
PAF 998d 263b 2.3b 0.0002c 0.00008d 0.00004d
TC 2078c 186c 3.6a 21.6a 85.6b 6200a
PE 416e 173c 12.4b 201.1a
* Concentration of activator allowing half maximal BSDL velocity. Different letters
in the columns means signiﬁcant difference between activators at P < 0.05.
Fig. 2. Taurocholate (A), (lyso)phosphatidic (B) and platelet activating factor (C)
stimulate hydrolysis of cholesteryl-oleate by BSDL. Saturating concentration of
cholesteryl-oleate (0.1 mM) was used with 10 nM of BSDL. The inserts show the
Michaelis–Menten plots at the lower concentrations of the activators.
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plex kinetic phenomena, likely involving the changes in the phys-
ical form of the triad cholesteryl-oleate/BSDL/effector. The catalytic
constant of breast milk BSDL on cholesteryl-oleate in the presence
of TC (3.6 s1, Table 1) ranges between that of BSDL from human
pancreas (1.3 s1, [1]) and that from porcine pancreas (57 s1,
[30]). Actually, as shown in Table 1, kcat with ChoC18 as substrate
varied only from 2.3 s1 to 3.6 s1, while changing the activator.
Interestingly, the stimulating effects were performed at dramati-
cally different concentrations depending on the activator. Indeed,
the apparent dissociation constant (which corresponds in the pres-
ent case to the activator concentration performing half maximal
BSDL velocity) varied from 40 pM (PAF) up to 6 mM (TC), PA and
LPA being in between (0.14 and 4.8 lM, respectively). Thus, PAF
stimulates BSDL at similar magnitude as TC but at 1.5 108-fold low-
er concentration. PAF and PA maximally activated BSDL through-
out two orders of magnitude concentration (0.2–20 nM for PAF
and 0.2–50 lM for PA), whereas LPA and TC exhibited peaks of con-
centrations that maximally activated BSDL at about 20 lM and
20 mM, respectively (Fig. 3).
The presence of negative charge in phospholipids was previ-
ously assumed to be a prerequisite for enzyme activation [25,26]
Fig. 3. Concentrations of taurocholate, (lyso)phosphatidic acid and platelet acti-
vating factor that stimulate hydrolysis of cholesteryl oleate by BSDL.
Fig. 4. BSDL velocity versus concentration of PNPC12 in the presence or absence of
taurocholate, (lyso)phosphatidic acid and platelet activating factor. The concentra-
tions of PA, LPA, PAF and TC were 20 lM, 20 lM, 1 nM and 200 lM, respectively,
and that of BSDL was 2 nM.
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distal BSDL basic clusters [26,31]. LPA, which harbour a negative
charge at neutral pH is revealed here as potent BSDL activator
and it behaved like PA with all the three substrates used. In this
connexion, it was previously reported that oxidized or acetylated
low density lipoproteins enhances the secretion of BSDL by human
monocyte–macrophages [32]. As well, LPA, which is a typical prod-
uct of oxidized LDL [33], could have stimulated the already se-
creted BSDL; so far, the authors did not show an increase in BSDL
in the mediums of cultured cells. Furthermore, many papers deal-
ing with BSDL structure–activity relationships mention that this
enzyme is active on phospholipids, but although exhaustive litera-
ture analysis we did not ﬁnd enzymatic data that conﬁrm this
assertion. If some studies have reported that BSDL is able to hydro-
lyse lysophosphatidylcholine [14,34], other studies have shown
that the activity of BSDL on cholesteryl-oleate or on triolein is
inhibited by phosphatidylcholine [35,36]. As shown in Fig. 1, PC
and LPC have had only slight effects or were inhibitors of BSDL
with PNPC4 and PNPPC12 as substrates. Thus, the absence of effects
of PC and LPC could be explained by their competitive hydrolysis
by BSDL rather than the absence of a net negative charge. Actually,
as these phospholipids are zwitterionic (at neutral pH), they could
bind to a basic cluster or individual basic BSDL residues. Con-
versely, BSDL is likely not able to hydrolyse the acidic phospholip-
ids PA and LPA, and the zwitterionic PAF, otherwise these three
compounds would not exhibit a Michaelian activation effects on
BSDL (Figs. 1 and 2). Therefore, the net negative charge is not nec-
essarily a prerequisite for BSDL activation.
The low apparent dissociation constants of these BSDL activa-
tors, especially PAF, rather suggests the existence of speciﬁc bind-
ing sites at the surface of the enzyme.
So far, the concentration of circulating PA was reported to be
50–150 lM [37], that of LPA below 100 nM in normal conditions
and increases up to 20 lM in pathological conditions [38]. Circulat-
ing PAF was reported to be in the pM–nM range depending on the
pathophysiological status [39,40]. These concentrations are in ade-
quacy with those performing maximal BSDL stimulation (Fig. 3),
suggesting that PA, LPA and PAF could modulate the extra-intesti-
nal activity of BSDL.
3.2. Effects of BSDL activators on the BSDL kinetic constants
In a subsequent set of kinetic experiments, we probed the ef-
fects of TC, PA, LPA and PAF on the BSDL kinetic constants (kcat
and Km) using PNPC12 as substrate. PNPC12 was chosen becauseBSDL displays the highest catalytic efﬁciency on the medium
length nitrophenyl esters, and PNPC12 exhibited the best Michae-
lis–Menten proﬁles [6]. The chosen concentrations in the case of
TC, PA, LPA and PAF (200, 20, 20 lM and 1 nM, respectively) were
those below the respective critical micelle concentration [1,41–
43]. So, each of them is expected to be present in a monomeric
form in the reaction medium.
In the presence of TC, PA, LPA or PAF, the plots of initial BSDL
velocity versus concentration of PNPC12 obeyed Michaelis–Menten
kinetic model, below 50 lM for TC and below 200 lM for the three
other BSDL activators (Fig. 4). PC, LPC and PE, which were tested
each at 200 lM promoted only slight increase, if any, of the initial
BSDL velocities on PNPC12 (data not shown).
The catalytic constants of BSDL on PNPC12 were calculated from
these kinetic data with correlation coefﬁcients above 0.96 in the
cases of basal, PA, LPA and PAF and equal to 0.91 in the case of
TC (Table 2).
Km of PNPC12 without any effector (11 lM) was less than half
that obtained in the presence of TC (25 lM), but the difference
was not signiﬁcant (P = 0.207), according to the statistical treat-
ment applied for comparing the BSDL effectors. Conversely, Km sig-
niﬁcantly increased (4- to 6-folds) in the presence of the three
other activators, following the rank LPA < PA < PAF (Table 2). Like-
wise, kcat of BSDL on PNPC12 increased 4- to 9-ﬂod in the presence
of activators following the rank TC < LPA < PA < PAF. In such a way,
interestingly, the catalytic efﬁciency (kcat/Km) of BSDL increased
ten folds with TC but only by half either with PA, LPA or PAF.
Accordingly, TC could be a non-competitive effector of PNPC12 for
binding to BSDL, whereas the kinetic behaviour of the three other
BSDL activators rather resembles that of uncompetitive ligands.
This means that TC could bind to both free BSDL and BSDL–PNPC12
complex, whereas LPA, PA and PAF could bind only to BSDL–
PNPC12 complex, suggesting the existence at least one binding site
for the three latter BSDL activators and two binding sites for TC.
The present data regarding TC support previous reports which evi-
denced the existence of two bile acid binding sites at the surface of
BSDL [1–3,6], one of them is located close to the active site [3].
Concerning the other BSDL activators, like PA, LPA could bind to
the proximal and/or distal clusters (K31,56,58,61,62-R63 and R423-
K429-R454,458-K462,503, respectively), as previously suggested based
Table 2
BSDL kinetic constants with PNPC12 as substrate in the presence or absence of
activators.
Activators kcat (s1) Km (lM)
PAF 553a 147a
PA 457b 124b
LPA 389c 102c
TC 284d 11d
Without 62e 25d
The kinetic constants were determined based on data of Fig. 4 using GraphPad
prism program with correlation constants of 0.98, 0.98, 0.96, 0.91 and 0.96 for PAF,
PA, LPA, TC and BSDL alone (without), respectively. The concentrations of PAF, PA,
LPA, and TC were 1 nM, 20 lM, 20 lM, and 200 lM, respectively. Different letters in
each column indicate signiﬁcant difference at P < 0.05.
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the effects of PAF on the kinetic parameters of BSDL were in the
same order of magnitude as those of PA and LPA as far as the sub-
strate was the aryl-ester PNPC12 (Fig. 4). However, it is more likely
that PAF has a highly speciﬁc binding site at the surface of BSDL,
given the very low apparent dissociation constants it exhibited
whatever the substrate used (Table 1).
4. Conclusions
The present study opens new perspectives regarding the extra-
intestinal function of BSDL. It is stimulated by physiological con-
centrations of phosphatidic acid, lyso-phosphatidic acid and plate-
let activating factor. These compounds could be extra-cellular
mediators that modulate circulating BSDL activity under normal
and abnormal conditions, especially lining with the metabolism
of lipoproteins. There is a need for additional studies including
the use of crystallography and mutagenesis and especially target-
ing identiﬁcation of the binding sites of PA, LPA and PAF and
how these effectors could modulate the extra-intestinal activity
of BSDL.
In addition to identiﬁcation of novel BSDL activators, the pres-
ent report proposes a simple and easy-handling kinetic approach
that could be useful tool for future studies on BSDL. The experi-
mental protocols may be adapted for using other substrates, such
as isolated lipoproteins, and for testing analogues of the presently
identiﬁed or other potential BSDL activators, including circulating
lipoxidation products.
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